# Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/atezolizumab-plus-cabozantinib-versus-cabozantinib-monotherapy-for-patients-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Sumanta K. Pal,Laurence Albigès,Piotr Tomczak,Cristina Suárez,Martin H. Voss,Guillermo de Velasco,Jad Chahoud,Anastasia Mochalova,Giuseppe Procopio,Hakim Mahammedi,Friedemann Zengerling,Chan Kim,Takahiro Osawa,Martín Ángel,Suyasha Gupta,Omara Khan,Guillaume Bergthold,Bo Liu,Melania Kalaitzidou,Mahrukh Huseni,Christian Scheffold,Thomas Powles,Toni K. Choueiri |
| Citations | 200 |
| DOI | 10.1016/s0140-6736(23)00922-4 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://pmc.ncbi.nlm.nih.gov/articles/PMC11017728/pdf/nihms-1980340.pdf |
| OpenAlex ID | https://openalex.org/W4379389239 |
| PMID | 37290461 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Takahiro Osawa](https://scholariq.org/researchers/takahiro-osawa/)
- [Toni K. Choueiri](https://scholariq.org/researchers/toni-k-choueiri/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.